Goals · Specialty & Clinical
Glycemic control. Includes FDA-approved GLP-1 agonists, metformin-adjacent compounds.
Compounds linked to this goal in the catalogue, ordered by role — primary, then support, then optional. Roles follow peptide-db's per-use effectiveness rating (most effective → primary, effective → support, moderate or thinner → optional); a compound that reaches the goal through a curated stack or a condition page says so. Click any card for the full mechanism, dosing, and evidence.
Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
Half-life: ~7 days (159-195 hours)
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Half-life: 6-8 days
Oral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes
Half-life: 25-68 hours
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Half-life: ~6 days
GLP-1 Receptor Agonist | Weight Loss & Diabetes
Half-life: ~7 days (168 hours)
Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes
Half-life: ~5 days (120 hours)
KEDW Tetrapeptide | Pancreas Bioregulator
Half-life: Not established
Support — Pancreatic Cell Differentiation · effective
Amino Acid Derivative | Fatty Acid Transporter
Half-life: ~2-3 hours (injectable)
Optional — Curated stack: GLP-1 Fat-Loss Starter
No SARMs tagged for this goal yet.
Biguanide | AMPK Activator & Longevity Research
Half-life: ~5 hours
Support — Researched for Type 2 Diabetes
Plant Alkaloid | Natural Glucose & Lipid Management
Half-life: ~4 hours
Optional — Researched for Type 2 Diabetes